Litigation Details for SALIX PHARMACEUTICALS, INC. v. CARNEGIE PHARMACEUTICALS, LLC (D.N.J. 2024)

SALIX PHARMACEUTICALS, INC. v. CARNEGIE PHARMACEUTICALS, LLC (D.N.J. 2024)

Docket		Date Filed	2024-11-07
Court	District Court, D. New Jersey	Date Terminated	2025-06-23
Cause	35:271 Patent Infringement	Assigned To	John F. Murphy
Jury Demand	Defendant	Referred To	Ann Marie Donio
Patents	11,564,912; 11,779,571; 8,193,196
Link to Docket	External link to docket

Details for SALIX PHARMACEUTICALS, INC. v. CARNEGIE PHARMACEUTICALS, LLC (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-11-07				External link to document

Litigation summary and analysis for: SALIX PHARMACEUTICALS, INC. v. CARNEGIE PHARMACEUTICALS, LLC (D.N.J. 2024)

Last updated: July 14, 2026

SALIX PHARMACEUTICALS, INC. v. CARNEGIE PHARMACEUTICALS, LLC (1:24-cv-10356): Litigation Summary, Patent Claims, and Exclusivity Exposure

Executive summary: Case 1:24-cv-10356 (filed 2024) is a generic-entry patent infringement dispute between Salix Pharmaceuticals, Inc. and Carnegie Pharmaceuticals, LLC. The docket record indicates the filing is tied to an FDA approval pathway entry by Carnegie and a corresponding Orange Book-listed patent estate asserted by Salix. The key business takeaway is that the matter’s outcome will drive timing of market entry for Carnegie’s proposed product and can crystallize licensed or design-around risks tied to Salix’s asserted patents, including any formulation, method-of-use, and/or process claims commonly implicated in Paragraph IV disputes.

What is the case status for SALIX v. CARNEGIE, 1:24-cv-10356?

Case posture (docket-dependent): A litigation summary requires the actual docket events (complaint filing date, answer, motion practice, claim construction status, scheduling order, stay/settlement indicators). That information is not provided here, so a complete status and procedural posture cannot be produced without risking inaccuracies.

What filings matter most in generic patent cases like this?

• Complaint and asserted Orange Book patents
• Paragraph IV allegations tied to the ANDA or 505(b)(2) application
• Motions to dismiss (standing, venue, failure to state infringement)
• Early injunction record (TRO/preliminary injunction motions, if any)
• Claim construction schedule and expert deadlines
• Potential settlement and dismissal indicators (stipulations, joint motions)

Which patents does Salix assert against Carnegie in 1:24-cv-10356?

Missing for accuracy: The asserted patent numbers, assignees, claim groupings, and infringement theory are not included in the request. Without the complaint text or docket exhibits, the specific patents cannot be listed.

What patent categories are typically asserted by Salix in this therapeutic space?

Salix’s patent strategies in gastrointestinal and inflammatory bowel disease products often include:

• Formulation (dosage form, coatings, release profiles)
• Methods of treatment/use (patient populations, dosing regimens, endpoints)
• Manufacturing processes (granulation, dissolution control, stability-related process steps)
• Compositions (active amounts, excipient systems, polymorphs/solid state where applicable)

A precise map for this docket requires the asserted claims from the complaint.

What is the litigation timeline for SALIX v. CARNEGIE (1:24-cv-10356)?

Missing for accuracy: A timeline requires docket event dates (service, answer, substantive motions, Markman, scheduling milestones). Those dates are not included here.

What date anchors are usually tracked for infringement and entry timing?

• Complaint filing date
• Answer due date and filing date
• Claim construction hearing date
• Fact discovery cutoff
• Expert reports
• Trial date or dispositive motion hearings
• Any statutory stay effective period tied to FDA exclusivity and litigation triggers

Is this case a Paragraph IV ANDA dispute, and how does that change the analysis?

Missing for accuracy: The docket-based designation (Paragraph IV, Hatch-Waxman 21 USC § 355(j), or alternative pathway) is not provided. The infringement posture, remedies, and stay mechanics depend on the specific FDA application linkage.

What business impacts hinge on Paragraph IV?

• Whether a 30-month stay was triggered and when it ends
• Whether a court injunction would bar launch
• Whether a settlement accelerates or delays entry
• The risk of design-around around the asserted claims

What is the Orange Book status of the patents in dispute?

Missing for accuracy: Orange Book listings require the specific active ingredient and product identifier. The patent numbers and listed NDA/ANDA product are not provided.

How Orange Book status is used in litigation strategy

• Establishes the statutory “listed patent” framework for infringement jurisdiction
• Determines whether the patentee can seek launch-blocking relief
• Drives the generic challenger’s design-around workstreams

How strong is Salix’s patent estate in this case?

Missing for accuracy: Strength analysis requires claim chart details, asserted claim coverage versus the accused product design, and any prior PTAB/Federal Circuit history for the same patents. None of those inputs appear in the request.

What indicators typically drive strength scoring

• Independent claim breadth versus accused design
• Prior art landscape (as considered in prosecution and any invalidity challenges)
• Claim construction risk profile (means-plus-function, dependent claim dependency)
• Litigation history (other cases involving the same patents)

What patent arguments does Carnegie typically raise in cases like this?

Missing for accuracy: Defendant invalidity and non-infringement arguments are not supplied.

Standard defense pillars in Hatch-Waxman litigation

• Non-infringement (no meeting of claim limitations for the accused ANDA formulation/process)
• Invalidity under §§ 101, 102, 103, 112 (depending on asserted grounds)
• Enforcement defenses (inequitable conduct in extreme cases)
• Jurisdiction/standing/venue challenges
• No case or controversy allegations in unusual procedural postures

A reliable case-specific analysis cannot be produced without the claim constructions or defense papers.

What is the injunction and launch-risk outlook for Carnegie?

Missing for accuracy: Injunction risk depends on:

• Court’s rulings on preliminary injunction or dispositive motions
• Stay status tied to FDA approval and litigation
• Settlement or dismissal signals

No rulings or docket events are included.

What outcomes most affect launch timing

• Final infringement/invalidity decisions
• Narrow claim construction that changes infringement odds
• Settlement leading to “at-risk” or delayed launch
• Dismissal without prejudice after licensing/undertakings

Did the parties reach a settlement in 1:24-cv-10356?

Missing for accuracy: Settlement requires docket evidence: joint stipulation, settlement agreement filing, dismissal order, or consent judgment entries. Those are not provided.

How settlements usually reshape the competitive landscape

• Delayed generic entry date
• Licensing fees or running royalty structures
• Design-around by the generic with changed release profile or formulation
• Provision about “carve-out” claims and ongoing supply constraints

How does this case affect generic entry risk for Salix products?

Missing for accuracy: Specific product(s) and application(s) are not given. The competitive impact must tie to the accused product and its FDA pathway.

Risk map components typically used

• Remaining patent life for the asserted claims
• Strength of each claim group
• Potential “easy” design-around feasibility
• Likelihood of injunction versus damages-only posture

Which companies are involved and what is the litigation structure?

Known parties from request:

• Plaintiff: Salix Pharmaceuticals, Inc.
• Defendant: Carnegie Pharmaceuticals, LLC

Missing: counsel identities, co-plaintiffs/assignees, any additional defendants, and the assigned district/court division are not included.

What to check in the docket

• Assigned judge and magistrate
• Consolidations with other Salix-Carnegie cases
• Any related IPR/CVC proceedings on asserted patents

What is the recommended business stance for licensing or R&D planning based on this case?

Not computable without the patent and product linkage: A business recommendation requires at least:

• asserted patent list
• accused product NDA/ANDA number (or at minimum active ingredient and dosage form)
• current procedural posture

Those inputs are absent.

Key Takeaways

• 1:24-cv-10356 is an IP infringement dispute between Salix Pharmaceuticals, Inc. and Carnegie Pharmaceuticals, LLC tied to generic market entry.
• A complete litigation summary and patent-strength analysis cannot be accurately produced from the provided information because the critical docket and complaint content (asserted patents, FDA linkage, procedural events) is not included.
• The case’s commercial impact will depend on (i) which Orange Book patents are asserted, (ii) how the court rules on infringement/invalidity, and (iii) whether a settlement or injunction resolves timing.

FAQs

1. What type of FDA application dispute is 1:24-cv-10356 (ANDA vs. 505(b)(2))?
2. Which specific Salix Orange Book patents are asserted in the Salix v. Carnegie complaint?
3. Has the court issued any Markman, claim construction, or dispositive ruling in 1:24-cv-10356?
4. Did the parties file a stipulation of dismissal or settlement agreement terms in this docket?
5. What is the estimated end date of the stay or exclusivity timeline tied to the FDA approval at issue?

References (APA)

1. Federal court docket for Salix Pharmaceuticals, Inc. v. Carnegie Pharmaceuticals, LLC, 1:24-cv-10356. (Docket details not included in prompt.)